Provided by Tiger Trade Technology Pte. Ltd.

Halozyme Therapeutics

108.44
+2.192.06%
Post-market: 106.51-1.9300-1.78%16:50 EDT
Volume:1.70M
Turnover:183.83M
Market Cap:12.31B
PE:32.06
High:109.63
Open:106.66
Low:105.50
Close:106.25
52wk High:111.15
52wk Low:61.23
Shares:113.50M
Float Shares:112.00M
Volume Ratio:1.41
T/O Rate:1.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.38
EPS(LYR):2.56
ROE:173.67%
ROA:25.49%
PB:85.74
PE(LYR):42.36

Loading ...

U.S. Earnings Preview: After Market Close May 11

Dow Jones
·
May 12

Halozyme Therapeutics Inc expected to post earnings of $1.53 a share - Earnings Preview

Reuters
·
May 09

Halozyme shareholders approve Ernst & Young as 2026 auditor at annual meeting

Reuters
·
May 08

Halozyme announces global collaboration and license agreement with GSK

TIPRANKS
·
May 08

BRIEF-Halozyme Announces Global Collaboration And License Agreement With Gsk To Develop Subcutaneous Formulations Of Multiple Promising Oncology Targets

Reuters
·
May 07

Halozyme inks global ENHANZE licensing deal with GSK for subcutaneous oncology drugs

Reuters
·
May 07

Halozyme Therapeutics Inc - Collaboration Includes Option for Additional Future Targets

THOMSON REUTERS
·
May 07

Halozyme Therapeutics Inc - First Clinical Trial Projected to Initiate in 2026

THOMSON REUTERS
·
May 07

Halozyme Therapeutics Inc - GSK to Make Upfront and Milestone Payments; Halozyme Entitled to Royalties

THOMSON REUTERS
·
May 07

Halozyme Announces Global Collaboration and License Agreement With GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets

THOMSON REUTERS
·
May 07

Halozyme, Oruka sign global license to develop ORKA-001 using Hypercon technology

Reuters
·
May 06

Halozyme Therapeutics Inc - Oruka to Make Upfront and Milestone Payments; Halozyme Eligible for Mid-Single Digit Royalties

THOMSON REUTERS
·
May 06

Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop Orka-001 With Hypercon™ Technology

THOMSON REUTERS
·
May 06

Exports Triple in Six Years, HALO Value Reassessment: Huatai-PB Engineering Machinery ETF Launches on May 6

Deep News
·
May 06

Halozyme Director Bernadette Connaughton sells 1,625 shares worth $103,155.00

Reuters
·
May 06

Earning Preview: Halozyme Therapeutics this quarter’s revenue is expected to increase by 55.99%, and institutional views are bullish

Earnings Agent
·
May 05

Halozyme to report first-quarter results after market close May 11

Reuters
·
May 01

Johnson & Johnson names Ryan Koors vice president of investor relations

Reuters
·
Apr 30

Halozyme appoints Darren Snellgrove CFO, effective June 8

Reuters
·
Apr 30

Halozyme Appoints Darren Snellgrove as Chief Financial Officer

THOMSON REUTERS
·
Apr 30